At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
emixustat hydrochloride +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Pilot Study to Evaluate Effects of Emixustat Hydrochloride on Aqueous Humor Biomarkers Associated With Proliferative Diabetic Retinopathy
In Brief
A Phase 2 clinical trial evaluating emixustat hydrochloride and Placebo for Proliferative Diabetic Retinopathy. Completed, enrolled 24 participants across 1 site.
Detailed Summary
To evaluate the effects of oral emixustat hydrochloride (emixustat) on aqueous humor biomarkers associated with proliferative diabetic retinopathy (PDR) from baseline to week 12.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProliferative Diabetic Retinopathy
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartMay 2016
Primary CompletionNov 2017
Study CompletionDec 2017
TodayJul 2026
First PostedApr 27, 2016
Enrollment StartMay 1, 2016
Primary CompletionNov 1, 2017
Study CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.2 years ago
Interventions
emixustat hydrochloridedrug
Tablet for oral administration
Placeboother
Placebo tablets for oral administration contain only inactive ingredients